165800-06-6
165800-06-6 結構式
基本信息
唑來磷酸一水化合物
(1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid hydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid monohydrate
PHOSPHONIC ACID, [1-HYDROXY-2-(1H-IMIDAZOL-1-YL)ETHYLIDENE]BIS-, MONOHYDRATE
zoledronic acid hydrate
ZOLEDRONIC ACID MONOHYDRATE
ZoledronicacidforInjection
物理化學性質
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/11 | XW1658000662 | 唑來磷酸一水化合物 | 165800-06-6 | 5G | 544元 |
| 2024/11/11 | XW1658000661 | 唑來磷酸一水化合物 | 165800-06-6 | 1G | 146元 |
| 2024/11/08 | 46621 | 唑來磷酸 Zoledronic acid monohydrate | 165800-06-6 | 1g | 853元 |
常見問題列表
| Target | Value |
|
Ras
() | |
|
Rho
() |
Zoledronic Acid monohydrate (0.1-1 μM; 48 hours) increases receptor activator of nuclear factor kB ligand (RANKL) and sclerostin mRNA expressions in osteocyte-like MLO-Y4 cells.
Zoledronic Acid monohydrate increases the expression of osteoclastogenesis supporting factor from MLO-Y4 cells.
Zoledronic Acid monohydrate enhances the RANKL expression via IL-6/ JAK2/STAT3 pathway in MLO-Y4 cells.
Zoledronic Acid monohydrate inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.
Zoledronic Acid monohydrate (10-100 μM; 1-7 days) markedly reduces the viability of MC3T3-E1 cells.
Zoledronic Acid monohydrate (10-100 μM; 1-7 days) induces apoptosis in MC3T3-E1 cells.
Zoledronic Acid monohydrate (10-100 μM; 4 days) inhibits cell viability due to the induction of apoptosis.
Zoledronic Acid monohydrate exerts inhibitory effects on the differentiation and maturation of MC3T3-E1 cells at concentrations <1 μM.
Cell Viability Assay
| Cell Line: | MC3T3-E1 cells |
| Concentration: | 0.02 μM , 0.1 μM, 1 μM, 10 μM, 100 μM |
| Incubation Time: | 1 day, 3 days, 5 days, 7 days |
| Result: | Reduced cells viability at 10 μM and 100 μM. |
Apoptosis Analysis
| Cell Line: | MC3T3-E1 cells |
| Concentration: | 0.02 μM , 0.1 μM, 1 μM, 10 μM, 100 μM |
| Incubation Time: | 1 days, 4 days, 7 days |
| Result: | Increased the number of early apoptotic cells and late apoptotic or necrotic cells at dose-dependent and time-dependent (high concentrations). |
Western Blot Analysis
| Cell Line: | MC3T3-E1 cells |
| Concentration: | 0.02 μM , 0.1 μM, 1 μM, 10 μM, 100 μM |
| Incubation Time: | 4 days |
| Result: | Down-regulated the protein level of inactive caspase-3 and up-regulated the protein level of active caspase-3 at the concentrations of 10 and 100 μM. |
Zoledronic Acid monohydrate (0.05 mg/kg; i.p.; weekly; for 3 weeks) increases bone mineral density and content.
Zoledronic Acid monohydrate (0.5-1 mg/kg; i.p.; weekly; for 3 weeks) inhibits both osteoclast and osteoblasts function and bone remodeling in vivo interfering with bone mechanical properties.
| Animal Model: | Five-week-old C57BL6 mice |
| Dosage: | 0.05 mg/kg, 0.5 mg/kg, 1 mg/kg |
| Administration: | Intraperitoneal injection, weekly, for 3 weeks |
| Result: | Inhibited both osteoclast and osteoblasts function and bone remodeling at 0.5 mg/kg and 1 mg/kg. |